BBA
NBIX icon

Baader Bank Aktiengesellschaft’s Neurocrine Biosciences NBIX Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Buy
+2,500
New +$371K 0.03% 311
2024
Q2 		– Sell
-4,600
Closed -$634K – 460
2024
Q1 		$634K Buy
+4,600
New +$628K 0.05% 221
2023
Q1 		– Sell
-1,700
Closed -$203K – 443
2022
Q4 		$203K Buy
+1,700
New +$199K 0.01% 327

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Baader Bank Aktiengesellschaft's NBIX Position: Q2 2026 in Review

Baader Bank Aktiengesellschaft opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,500 shares worth $421K. The stake represents 0.03% of the portfolio and ranks #311 among its holdings. This is a return to the name: Baader Bank Aktiengesellschaft previously reported a position in NBIX as recently as Q1 2024.

Baader Bank Aktiengesellschaft first reported a position in NBIX in Q4 2022 and has held it in 3 quarters since. The position peaked at $634K in Q1 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Baader Bank Aktiengesellschaft held 2,500 shares of Neurocrine Biosciences worth $421K as of Q2 2026.
  • Neurocrine Biosciences was a new Baader Bank Aktiengesellschaft position in Q2 2026.
  • Neurocrine Biosciences made up 0.03% of Baader Bank Aktiengesellschaft's portfolio in Q2 2026, its #311 holding.
  • Baader Bank Aktiengesellschaft first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 3 quarters since.
  • Baader Bank Aktiengesellschaft's Neurocrine Biosciences position peaked at $634K in Q1 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2026, filed 23 Jul 2026.